
Roche announced that its phase 3 IMpower150 study determined that the combination of drug atezolizumab (Tecentriq) to bevacizumab (Avastin) with the chemotherapy drugs paclitaxel and carboplatin showed a significant reduction in the risk of disease worsening or death compared to Avastin plus chemotherapy in the first-line treatment of patients with non-small cell lung cancer (NSCLC).


















